A Phase III Randomized Trial of Gemcitabine (NSC 613327) Plus Docetaxel (NSC 628503) Followed by Doxorubicin (NSC 123127) Versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma

Trial Profile

A Phase III Randomized Trial of Gemcitabine (NSC 613327) Plus Docetaxel (NSC 628503) Followed by Doxorubicin (NSC 123127) Versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Docetaxel (Primary) ; Doxorubicin (Primary) ; Gemcitabine (Primary) ; Filgrastim; Pegfilgrastim
  • Indications Leiomyosarcoma; Uterine cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jun 2018 Results (n=38) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 30 Jan 2018 This trial has been completed in France (End Date: 2017-03-23).
    • 23 Aug 2017 Planned primary completion date changed from 1 Feb 2018 to 30 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top